CKB
Ckb creatine kinase, brain
CKB; creatine kinase, brain; creatine kinase B-type; creatine kinase B chain; Bck; Ck3; B-CK; Ck-3; Ckbb;
CHKB
choline kinase beta
CHKB; choline kinase beta; CHKL, choline kinase like; choline/ethanolamine kinase; CHETK; Chetk-beta; Chkb choline kinase beta; Chkb protein; CHKB_HUMAN; CHKL; Choline kinase-like; Choline kinase-like protein; choline/ethanolamine kinase beta; Choline/ethanolamine kinase, beta; CK; CK/EK; CK/EK-beta; CKB; CKEKB; EK; EKB; Ethanolamine kinase; Ethanolamine kinase beta; Ethanolamine kinase, beta; MDCMC;
Cell: the “Protein backbone” of the Yeast Telosome
A model of the Rap1-Rif1-Rif2 Assembly at Telomeres Researchers have made a molecular, biochemical, and functional dissection on the protein backbone at the core of the yeast telosome. Repeated sequences form the genome as the sequence motif links sequence motif as well as binds proteins. Thes...
Worldwide Blockbusters’ Movements during Sep., 2013
On Sep. 23, 2013, Ablynx landed $840M AbbVie deal on next-gen Humira successor. Based on this, AbbVie has whipped out the checkbook to close a partnership with Belgian antibody specialist Ablynx on one of its lead programs, paying $175 million upfront and promising up to $665 million more in milesto...
Worldwide Blockbusters' Movements (Alliance and Collaboration within this December)
On Dec. 20, 2012, CEVEC Pharmaceuticals (CEVEC), the developer of a novel human expression system derived from amniocytes, and Yuhan Corporation (Yuhan) based in Seoul, South Korea announced the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilize CEVEC's CAP-T and...
Worldwide Blockbusters’ Movements (Alliance and Collaboration within this December)
On Dec. 20, 2012, CEVEC Pharmaceuticals (CEVEC), the developer of a novel human expression system derived from amniocytes, and Yuhan Corporation (Yuhan) based in Seoul, South Korea announced the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilize CEVECs CAP-T...
The Last FDA Approvals in 2012 for World Pharma Regulatory Blockbusters (From Dec. 21 to Dec. 31)
On Dec. 31, 2012, the last day of the year, the FDA came through with a rapid-fire approval of Johnson Johnson's bedaquiline, the first new treatment for drug-resistant tuberculosis in four decades. The approval was based on mid-stage data after JJ ($JNJ) made its case that the urgent nee...
Worldwide Blockbusters’ Movements during Feb., 2013
GlaxoSmithKline (GSK) has joined up with investigators at Vanderbilt University to quick march their preclinical work on a new obesity drug into clinical studies. The pharma giant has been warming up to Roger Cone and his Vanderbilt team. With significant backing from the NIH, they have...
